Xiangxue Pharmaceutical (300147) — Cash Flow Reinvestment Rate
Xiangxue Pharmaceutical (300147) has a Cash Flow Reinvestment Rate of 0.08x as of September 2025, reinvesting CN¥5.74 Million (capex CN¥5.74 Million ) from operating cash flow of CN¥75.64 Million. See cash generation quality of Xiangxue Pharmaceutical to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Xiangxue Pharmaceutical Cash Flow Reinvestment Rate (2007–2025)
Historical reinvestment intensity for Xiangxue Pharmaceutical across 19 annual periods. For the full cash flow conversion analysis, see Xiangxue Pharmaceutical (300147) cash flow conversion.
Annual Cash Flow Reinvestment Rate for Xiangxue Pharmaceutical (2007–2025)
Year-by-year capital reinvestment analysis for Xiangxue Pharmaceutical. See 300147 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.18x | CN¥25.47 Million | CN¥139.63 Million | CN¥21.51 Million | ▼ -94.4% |
| 2024 | 3.24x | CN¥58.95 Million | CN¥18.17 Million | CN¥35.24 Million | ▲ +678.9% |
| 2023 | 0.42x | CN¥109.69 Million | CN¥263.44 Million | CN¥56.03 Million | ▼ -77.7% |
| 2022 | 1.87x | CN¥425.18 Million | CN¥227.38 Million | CN¥367.27 Million | ▼ -21.2% |
| 2021 | 2.37x | CN¥611.43 Million | CN¥257.56 Million | CN¥562.74 Million | ▼ -15.2% |
| 2020 | 2.80x | CN¥719.65 Million | CN¥257.18 Million | CN¥707.42 Million | ▼ -77.3% |
| 2019 | 12.34x | CN¥1.02 Billion | CN¥83.02 Million | CN¥661.09 Million | ▲ +82.4% |
| 2018 | 6.76x | CN¥617.05 Million | CN¥91.24 Million | CN¥495.46 Million | ▼ -19.3% |
| 2017 | 8.38x | CN¥917.76 Million | CN¥109.53 Million | CN¥777.87 Million | ▼ -23.6% |
| 2016 | 10.97x | CN¥2.18 Billion | CN¥198.48 Million | CN¥1.97 Billion | ▲ +183.3% |
| 2015 | 3.87x | CN¥618.83 Million | CN¥159.89 Million | CN¥276.95 Million | ▲ +162.8% |
| 2014 | 1.47x | CN¥243.85 Million | CN¥165.58 Million | CN¥243.85 Million | ▲ +51.8% |
| 2013 | 0.97x | CN¥318.55 Million | CN¥328.37 Million | CN¥318.55 Million | ▼ -72.4% |
| 2012 | 3.52x | CN¥418.12 Million | CN¥118.91 Million | CN¥418.12 Million | ▼ -55.0% |
| 2011 | 7.81x | CN¥230.69 Million | CN¥29.55 Million | CN¥230.69 Million | ▲ +524.1% |
| 2010 | 1.25x | CN¥56.87 Million | CN¥45.47 Million | CN¥56.87 Million | ▲ +9.3% |
| 2009 | 1.14x | CN¥52.86 Million | CN¥46.19 Million | CN¥52.86 Million | ▼ -53.7% |
| 2008 | 2.47x | CN¥137.71 Million | CN¥55.72 Million | CN¥137.71 Million | ▲ +135.7% |
| 2007 | 1.05x | CN¥144.73 Million | CN¥138.02 Million | CN¥144.73 Million | — |